NHS access to promising sleeping pill daridorexant is patchy, say doctors
The article discusses the limited NHS access to the promising new sleeping pill, daridorexant, in England. Key points: - Daridorexant, a non-addictive sleeping pill approved in 2022, has been prescribed 67,000 times since November 2023, costing the NHS an estimated £2.6m. - The drug is hailed for helping people fall asleep faster, stay asleep longer, and wake up clear-headed, without the dependency risks of traditional sleeping pills. - However, doctors say NHS uptake of daridorexant is being held back by cost and patchy awareness, with prescribing clustered in London and the West Midlands, while a cheaper alternative is issued far more often. - The article suggests that the limited access to this promising new treatment may be denying patients the benefits of a non-addictive sleep aid.
Source: For the complete article, please visit the original source link below.
